Bora Pharmaceuticals Co., LTD.

TWSE:6472 Stock Report

Market Cap: NT$77.2b

Bora Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Bora Pharmaceuticals has been growing earnings at an average annual rate of 48.8%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 47.1% per year. Bora Pharmaceuticals's return on equity is 28.7%, and it has net margins of 23.3%.

Key information

48.8%

Earnings growth rate

47.4%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate47.1%
Return on equity28.7%
Net Margin23.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Recent updates

Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?

Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Apr 30
Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Mar 17
Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Feb 17
Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Jan 27
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Jan 19
Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Dec 29
We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Dec 09
Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Revenue & Expenses Breakdown

How Bora Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:6472 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2416,7053,9002,977565
30 Jun 2414,1663,1872,347462
31 Mar 2412,2772,7071,641336
31 Dec 2314,2003,0301,444298
30 Sep 2316,2932,8681,344272
30 Jun 2315,9422,7041,212238
31 Mar 2314,1582,2521,056176
31 Dec 2210,4941,392862129
30 Sep 226,3461,12868757
30 Jun 224,81169758638
31 Mar 224,65059457141
31 Dec 214,90075058541
30 Sep 214,4181,04563740
30 Jun 213,62696357839
31 Mar 212,79486850737
31 Dec 201,80057844137
30 Sep 201,52319130037
30 Jun 201,51323229338
31 Mar 201,52126228039
31 Dec 191,52930525940
30 Sep 191,51735521738
30 Jun 191,49228323641
31 Mar 191,51526722741
31 Dec 181,37244322038
30 Sep 181,10735120036
30 Jun 1884633014128
31 Mar 1852527411623
31 Dec 17358148720
30 Sep 17323178119
30 Jun 17297227418
31 Mar 17291247318
31 Dec 16283257118
30 Sep 16273236818
30 Jun 16260186918
31 Mar 16247266717
31 Dec 15238346517
30 Sep 15236306513
30 Jun 15234286812
31 Mar 15226236510
31 Dec 1421817629
30 Sep 1418216549
30 Jun 1415416448
31 Mar 1412310416

Quality Earnings: 6472 has a large one-off gain of NT$1.3B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 6472's current net profit margins (23.3%) are higher than last year (17.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6472's earnings have grown significantly by 48.8% per year over the past 5 years.

Accelerating Growth: 6472's earnings growth over the past year (36%) is below its 5-year average (48.8% per year).

Earnings vs Industry: 6472 earnings growth over the past year (36%) exceeded the Pharmaceuticals industry 11.9%.

Return on Equity

High ROE: Whilst 6472's Return on Equity (28.66%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:11
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bora Pharmaceuticals Co., LTD. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jianzheng WuCapital Securities Corporation
null nullCapital Securities Corporation
Hsuan ChenKGI Securities Co. Ltd.